Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

This study has been completed.
Information provided by (Responsible Party):
Avanir Pharmaceuticals
ClinicalTrials.gov Identifier:
First received: April 23, 2012
Last updated: September 18, 2014
Last verified: September 2014
The objectives of the study are to evaluate the safety, tolerability and efficacy of AVP-923 compared to placebo, for the treatment of symptoms of agitation in patients with Alzheimer's Disease (AD).

Condition Intervention Phase
Alzheimer's Disease
Drug: AVP-923 (dextromethorphan/quinidine)
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.

Resource links provided by NLM:

Further study details as provided by Avanir Pharmaceuticals:

Primary Outcome Measures:
  • Neuropsychiatric Inventory (NPI) [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]
    Primary Endpoint: Agitation/Aggression Domain of NPI

Secondary Outcome Measures:
  • Safety and Tolerability [ Time Frame: 10 weeks ] [ Designated as safety issue: Yes ]
    Standard Measurements (e.g. AEs, ECG, Labs, PE and Neuro Exam)

  • Neuropsychiatric Inventory (NPI) [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]
    Total NPI

  • Neuropsychiatric Inventory (NPI) [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]
    Caregiver Distress for NPI Domains

  • Neuropsychiatric Inventory (NPI) [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]
    NPI-4A (Composite of 4 NPI Domains)

  • Neuropsychiatric Inventory (NPI) [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]
    NPI-4D (Composite of 4 NPI Domains)

  • Neuropsychiatric Inventory (NPI) [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]
    Individual Domains of NPI

  • ADCS-CGIC (Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change Rating) [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]
    Agitation and Overall

  • PGIC Patient Global Impression of Change (PGI-C) [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]
    Agitation (Rated by Caregiver)

  • QoL-AD (Quality of Life - Alzheimer's Disease measure) [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]
  • ADCS-ADL (Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory) [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]
  • CSI (Caregiver Strain Index) [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]
  • CSDD (Cornell Scale for Depression in Dementia) [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]
  • (MMSE) Mini-Mental State Examination [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]

Enrollment: 220
Study Start Date: June 2012
Study Completion Date: September 2014
Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo Drug: Placebo
Placebo capsules administered twice a day over a 10-week period
Experimental: AVP-923 Drug: AVP-923 (dextromethorphan/quinidine)
AVP-923 capsules administered twice a day over a 10-week period

Detailed Description:

Eligible patients for this study must have a diagnosis of probable AD and must have clinically meaningful agitation secondary to AD.

This is a multicenter, randomized, double-dummy, double-blind, placebo-controlled study, consisting of 10 weeks of treatment.

Up to 200 patients will be enrolled at approximately 30-40 centers in the US.

Study medication will be administered orally twice-daily from Day 1 through Day 70. Screening must occur within within approximately 4 weeks prior to randomization. Following screening procedures for assessment of inclusion and exclusion criteria, eligible patients will be randomized into the study.


Ages Eligible for Study:   50 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

Diagnosis of probable Alzheimer's disease (AD).

The patient has clinically significant symptoms of agitation secondary to AD, that interfere with daily routine and for which a prescription medication is deemed indicated, in the opinion of the investigator.

Either out-patients or residents of an assisted-living facility or a skilled nursing home.

CGI-S score is ≥ 4 (moderately ill) at screening and baseline.

Mini Mental State Examination (MMSE) score at screening between 8 and 28 (inclusive).

Caregiver who is able and willing to comply with all required study procedures, ensuring that the patient attends all study visits and takes the study medication as instructed. In order to qualify as a caregiver for this study, the individual should spend time with the patient for a minimum of 4 hours on 4 separate days per week.

Key Exclusion Criteria:

Patient has other type of dementia (e.g., vascular dementia, frontotemporal dementia, Parkinson's disease, substance-induced dementia).

Patients with co-existent clinically significant or unstable systemic diseases that could confound the interpretation of the safety results of the study (e.g. malignancy, poorly controlled diabetes, poorly controlled hypertension, unstable pulmonary, renal or hepatic disease, unstable ischemic cardiac disease, dilated cardiomyopathy, certain cardiac conduction abnormalities including QTc prolongation, or unstable valvular heart disease).

Patients with myasthenia gravis.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01584440

  Hide Study Locations
United States, Arizona
Phoenix, Arizona, United States, 85006
Sun City, Arizona, United States, 85351
United States, California
Fresno, California, United States, 93720
Fullerton, California, United States, 92835
Los Angeles, California, United States, 90073
Los Angeles, California, United States, 90095
San Diego, California, United States, 92103
San Francisco, California, United States, 94109
Sherman Oaks, California, United States, 91403
Temecula, California, United States, 92591
United States, Florida
Boynton Beach, Florida, United States, 33426
Deerfield Beach, Florida, United States, 33064
Hialeah, Florida, United States, 33012
Miami, Florida, United States, 33122
Miami, Florida, United States, 33173
Miami, Florida, United States, 33137
Ocala, Florida, United States, 34471
Orlando, Florida, United States, 32806
Sunrise, Florida, United States, 33351
Tampa, Florida, United States, 33609
West Palm Beach, Florida, United States, 33407
West Palm Beach, Florida, United States, 33409
Weston, Florida, United States, 33331
United States, Illinois
Elk Grove Village, Illinois, United States, 60007
United States, Nevada
Las Vegas, Nevada, United States, 89106
Las Vegas, Nevada, United States, 89147
United States, New Jersey
Summit, New Jersey, United States, 07902
Toms River, New Jersey, United States, 08757
United States, New York
Orangeburg, New York, United States, 10962
Rochester, New York, United States, 14620
White Plains, New York, United States, 10605
United States, Ohio
Centerville, Ohio, United States, 45459
Cincinnati, Ohio, United States, 45227
Cleveland, Ohio, United States, 44195
Columbus, Ohio, United States, 43221
Lakewood, Ohio, United States, 44107
United States, Pennsylvania
Allentown, Pennsylvania, United States, 18104
Reading, Pennsylvania, United States, 19604
United States, South Carolina
Charleston, South Carolina, United States, 29401
United States, Texas
Houston, Texas, United States, 77030
San Antonio, Texas, United States, 78238
United States, Utah
Salt Lake City, Utah, United States, 84106
United States, Vermont
Bennington, Vermont, United States, 05201
United States, Washington
Spokane, Washington, United States, 99204
Sponsors and Collaborators
Avanir Pharmaceuticals
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Avanir Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01584440     History of Changes
Other Study ID Numbers: 12-AVR-131 
Study First Received: April 23, 2012
Last Updated: September 18, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Alzheimer Disease
Psychomotor Agitation
Brain Diseases
Central Nervous System Diseases
Mental Disorders
Nervous System Diseases
Neurobehavioral Manifestations
Neurocognitive Disorders
Neurodegenerative Diseases
Neurologic Manifestations
Psychomotor Disorders
Signs and Symptoms
Quinidine gluconate
Adrenergic Agents
Adrenergic Antagonists
Adrenergic alpha-Antagonists
Anti-Arrhythmia Agents
Anti-Infective Agents
Antiparasitic Agents
Antiprotozoal Agents
Antitussive Agents
Cholinergic Agents
Cholinergic Antagonists
Cytochrome P-450 CYP2D6 Inhibitors

ClinicalTrials.gov processed this record on May 23, 2016